Követés
Andy Z.X. Zhu
Andy Z.X. Zhu
E-mail megerősítve itt: utoronto.ca
Cím
Hivatkozott rá
Hivatkozott rá
Év
CYP2B6 and bupropion's smoking‐cessation pharmacology: the role of hydroxybupropion
AZX Zhu, LS Cox, N Nollen, B Faseru, KS Okuyemi, JS Ahluwalia, ...
Clinical Pharmacology & Therapeutics 92 (6), 771-777, 2012
107*2012
Effects of menthol on nicotine pharmacokinetic, pharmacology and dependence in mice
SD Alsharari, JR King, JC Nordman, PP Muldoon, A Jackson, AZX Zhu, ...
PloS one 10 (9), e0137070, 2015
1012015
The ability of plasma cotinine to predict nicotine and carcinogen exposure is altered by differences in CYP2A6: the influence of genetics, race, and sex
AZX Zhu, CC Renner, DK Hatsukami, GE Swan, C Lerman, NL Benowitz, ...
Cancer epidemiology, biomarkers & prevention 22 (4), 708-718, 2013
962013
Cannabinoid receptor stimulation increases motivation for nicotine and nicotine seeking
I Gamaleddin, C Wertheim, AZX Zhu, KM Coen, K Vemuri, A Makryannis, ...
Addiction biology 17 (1), 47-61, 2012
962012
Physiologically‐based pharmacokinetic modeling in renal and hepatic impairment populations: a pharmaceutical industry perspective
T Heimbach, Y Chen, J Chen, V Dixit, N Parrott, SA Peters, I Poggesi, ...
Clinical Pharmacology & Therapeutics 110 (2), 297-310, 2021
682021
Influence of CYP2B6 genetic variants on plasma and urine concentrations of bupropion and metabolites at steady state
NL Benowitz, AZX Zhu, RF Tyndale, D Dempsey, P Jacob III
Pharmacogenetics and genomics 23 (3), 135-141, 2013
672013
Alaska Native smokers and smokeless tobacco users with slower CYP2A6 activity have lower tobacco consumption, lower tobacco-specific nitrosamine exposure and lower tobacco …
AZX Zhu, MJ Binnington, CC Renner, AP Lanier, DK Hatsukami, ...
Carcinogenesis 34 (1), 93-101, 2013
582013
Pharmacogenetics of drug dependence: role of gene variations in susceptibility and treatment
JY Khokhar, CS Ferguson, AZX Zhu, RF Tyndale
Annual review of pharmacology and toxicology 50, 39-61, 2010
582010
Fasiglifam (TAK-875) alters bile acid homeostasis in rats and dogs: a potential cause of drug induced liver injury
FS Wolenski, AZX Zhu, M Johnson, S Yu, Y Moriya, T Ebihara, ...
Toxicological Sciences 157 (1), 50-61, 2017
552017
Association of CHRNA5‐A3‐B4 SNP rs2036527 With Smoking Cessation Therapy Response in African‐American Smokers
AZX Zhu, Q Zhou, LS Cox, SP David, JS Ahluwalia, NL Benowitz, ...
Clinical Pharmacology & Therapeutics 96 (2), 256-265, 2014
542014
Genome-wide meta-analysis of cotinine levels in cigarette smokers identifies locus at 4q13. 2
JJ Ware, X Chen, J Vink, A Loukola, C Minica, R Pool, Y Milaneschi, ...
Scientific reports 6 (1), 20092, 2016
502016
Quantitative systems pharmacology approaches for immuno‐oncology: adding virtual patients to the development paradigm
V Chelliah, G Lazarou, S Bhatnagar, JP Gibbs, M Nijsen, A Ray, B Stoll, ...
Clinical Pharmacology & Therapeutics 109 (3), 605-618, 2021
492021
Genome‐wide association study of a nicotine metabolism biomarker in African American smokers: impact of chromosome 19 genetic influences
MJ Chenoweth, JJ Ware, AZX Zhu, CB Cole, LS Cox, N Nollen, ...
Addiction 113 (3), 509-523, 2018
482018
CYP2A6 and CYP2B6 genetic variation and its association with nicotine metabolism in South Western Alaska Native people
MJ Binnington, AZX Zhu, CC Renner, AP Lanier, DK Hatsukami, ...
Pharmacogenetics and genomics 22 (6), 429-440, 2012
472012
Lack of Associations of CHRNA5-A3-B4 Genetic Variants with Smoking Cessation Treatment Outcomes in Caucasian Smokers despite Associations with Baseline …
RF Tyndale, AZX Zhu, TP George, P Cinciripini, LW Hawk Jr, RA Schnoll, ...
PloS one 10 (5), e0128109, 2015
462015
Novel CYP2A6 variants identified in African Americans are associated with slow nicotine metabolism in vitro and in vivo
M Piliguian, AZX Zhu, Q Zhou, NL Benowitz, JS Ahluwalia, LS Cox, ...
Pharmacogenetics and genomics 24 (2), 118-128, 2014
462014
Variation in trans-3′-hydroxycotinine glucuronidation does not alter the nicotine metabolite ratio or nicotine intake
AZX Zhu, Q Zhou, LS Cox, JS Ahluwalia, NL Benowitz, RF Tyndale
PLoS One 8 (8), e70938, 2013
442013
Effects of methoxsalen, a CYP2A5/6 inhibitor, on nicotine dependence behaviors in mice
D Bagdas, PP Muldoon, AZX Zhu, RF Tyndale, MI Damaj
Neuropharmacology 85, 67-72, 2014
392014
Recommendations for the design of clinical drug–drug interaction studies with itraconazole using a mechanistic physiologically‐based pharmacokinetic model
Y Chen, TD Cabalu, E Callegari, H Einolf, L Liu, N Parrott, SA Peters, ...
CPT: Pharmacometrics & Systems Pharmacology 8 (9), 685-695, 2019
312019
Quantitative translational modeling to facilitate preclinical to clinical efficacy & toxicity translation in oncology
AZX Zhu
Future science OA 4 (5), FSO306, 2018
312018
A rendszer jelenleg nem tudja elvégezni a műveletet. Próbálkozzon újra később.
Cikkek 1–20